Please login to the form below

Not currently logged in
Email:
Password:

Cancer disruptor F Star names next CEO

Dr Eliot Forster takes reins from Dr John Haurum

UK-based biotech F-star has named Dr Eliot Forster as its new chief executive.

Foster

Dr Eliot Forster, Incoming F-Star CEO

Based at the Babraham Research Campus in the Cambridge biotech cluster, the firm has been under the leadership of Dr John Haurum since it was set up in 2006. He is now handing over to Forster, who recently left another UK biotech, Oxford-based Immunocore.

While Immunocore is focused on novel immuno-oncology drugs, F-star specialises a new generation of bispecific antibodies, with cancer also its prime focus.

F-star has two assets in development, including its lead first-in-class, Merck KGaA-partnered candidate FS118, which works by simultaneously blocking two tumour growth promoting immune checkpoint molecules.

Dr Eliot Forster has been in the sector for more than 25 years, having served in senior positions for Pfizer and GSK.

At Immunocore, he helped the company raise a huge $320m during in a series A financing round – a feat which he may aim to duplicate at his new company.

“Over recent years, IO has transformed the oncology treatment paradigm, offering significantly better options to patients,” he says.

“The co-administration of immunotherapies is expected to be the next cornerstone in cancer treatments. I believe that F-star’s first-in-class molecules bring together in a single form, the full power of IO and combinations. We anticipate this synergistic benefit will deliver more targeted, potent and safer treatment options for cancer patients.”

The company has deals with the likes of Bristol-Myers Squibb, Merck KGaA and AbbVie.

16th October 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics